Taiwan Advance Bio-Pharmaceutical Inc. announced earnings results for the half year ended June 30, 2019. For the half year, the company announced total revenue was TWD 82.840 million compared to TWD 73.068 million a year ago. Operating loss was TWD 82.524 million compared to TWD 68.153 million a year ago. Net loss was TWD 86.144 million compared to TWD 18.986 million a year ago. Basic loss per share was TWD 1.2 compared to TWD 0.3 a year ago.